Orgenesis (ORGS) Competitors $0.10 -0.90 (-90.00%) As of 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. SYBX, LSB, HOTH, LPCN, LEXX, EDSA, COCP, BLRX, MTEX, and NRSNShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Synlogic (SYBX), LakeShore Biopharma (LSB), Hoth Therapeutics (HOTH), Lipocine (LPCN), Lexaria Bioscience (LEXX), Edesa Biotech (EDSA), Cocrystal Pharma (COCP), BioLineRx (BLRX), Mannatech (MTEX), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Its Competitors Synlogic LakeShore Biopharma Hoth Therapeutics Lipocine Lexaria Bioscience Edesa Biotech Cocrystal Pharma BioLineRx Mannatech NeuroSense Therapeutics Synlogic (NASDAQ:SYBX) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment. Does the media favor SYBX or ORGS? In the previous week, Orgenesis had 2 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Orgenesis and 0 mentions for Synlogic. Synlogic's average media sentiment score of 0.00 beat Orgenesis' score of -0.59 indicating that Synlogic is being referred to more favorably in the media. Company Overall Sentiment Synlogic Neutral Orgenesis Negative Do insiders and institutionals believe in SYBX or ORGS? 63.4% of Synlogic shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 3.0% of Synlogic shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, SYBX or ORGS? Synlogic has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Is SYBX or ORGS more profitable? Synlogic has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets SynlogicN/A -8.09% -5.50% Orgenesis -3,827.81%N/A -130.18% Which has preferable earnings and valuation, SYBX or ORGS? Synlogic has higher earnings, but lower revenue than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogicN/AN/A-$23.36M-$2.51-0.59Orgenesis$662K0.72-$55.36MN/AN/A SummarySynlogic beats Orgenesis on 6 of the 10 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$480K$828.28M$5.76B$9.72BDividend YieldN/A4.84%4.40%4.10%P/E RatioN/A1.1630.1925.84Price / Sales0.7226.80473.64122.75Price / CashN/A19.5625.7828.79Price / Book-0.026.659.425.99Net Income-$55.36M-$4.94M$3.27B$265.29M7 Day PerformanceN/A2.04%2.05%2.53%1 Month PerformanceN/A2.28%3.58%0.93%1 Year PerformanceN/A13.81%30.09%18.70% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesis1.295 of 5 stars$0.10-90.0%N/AN/A$480K$662K0.00150News CoverageNegative NewsSYBXSynlogicN/A$1.46+1.7%N/A-2.7%$17.02MN/A-0.5880LSBLakeShore BiopharmaN/A$0.81-1.0%N/A-81.4%$16.87M$85.67M0.00773HOTHHoth Therapeutics2.6001 of 5 stars$1.27-1.6%$4.00+215.0%+71.3%$16.84MN/A-1.194Positive NewsAnalyst DowngradeLPCNLipocine2.4149 of 5 stars$3.06+1.5%$9.00+194.6%-15.3%$16.56M$11.20M-3.5110News CoveragePositive NewsAnalyst RevisionLEXXLexaria Bioscience3.3551 of 5 stars$0.84+0.4%$4.00+376.2%-73.8%$16.43M$460K-1.257Gap UpEDSAEdesa Biotech1.5232 of 5 stars$2.33+2.6%$5.00+114.7%-46.1%$16.40MN/A-1.7620Gap UpCOCPCocrystal Pharma2.8588 of 5 stars$1.59+1.6%$6.00+278.5%-21.0%$16.37MN/A-1.2910Positive NewsBLRXBioLineRx3.3905 of 5 stars$3.82-0.2%$26.00+579.9%-87.3%$16.17M$28.94M-0.4340Gap UpMTEXMannatech0.2731 of 5 stars$8.43-1.4%N/A+21.6%$16.03M$112.98M-4.13250NRSNNeuroSense Therapeutics2.3502 of 5 stars$1.16-7.2%$14.00+1,106.9%+41.3%$15.93MN/A-2.1610 Related Companies and Tools Related Companies Synlogic Alternatives LakeShore Biopharma Alternatives Hoth Therapeutics Alternatives Lipocine Alternatives Lexaria Bioscience Alternatives Edesa Biotech Alternatives Cocrystal Pharma Alternatives BioLineRx Alternatives Mannatech Alternatives NeuroSense Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access